Opportunity Information: Apply for PAR 13 114
Apply for PAR 13 114
- The National Institutes of Health in the food and nutrition health sector is offering a public funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.351 Research Infrastructure Programs 93.837 Cardiovascular Diseases Research 93.846 Arthritis, Musculoskeletal and Skin Diseases Research 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research 93.859 Biomedical Research and Research Training.
- This funding opportunity was created on Feb 14, 2013 and posted on Feb 11, 2013.
- Applicants must submit their applications by May 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) Small businesses City or township governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public and State controlled institutions of higher education Independent school districts State governments For profit organizations other than small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) funding opportunity titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R01)" (Funding Opportunity Number PAR-13-114) supported Research Project Grant (R01) applications focused on making animal studies more useful and reliable for translating stem cell discoveries into real regenerative medicine therapies. The core purpose was to strengthen the scientific bridge between preclinical animal research and human clinical applications by improving how animal stem cells are understood, how stem cells are evaluated and delivered in vivo, and how animal disease models are designed to better mirror human conditions where stem cell-based interventions might eventually be used.
A major emphasis of the initiative was comparative work that directly examines similarities and differences between animal and human stem cells. The idea behind this priority was practical: if researchers can more clearly map where animal stem cell behavior matches human biology (and where it does not), they can choose the most predictive species, tissue types, and experimental systems for particular diseases or therapeutic strategies. This includes characterizing stem cell properties such as differentiation potential, self-renewal, lineage stability, functional integration, and responses to injury or disease environments, with the goal of identifying model systems that yield results most likely to hold up when moving into human trials.
The FOA also encouraged the creation and refinement of technologies that enable better stem cell characterization and transplantation in animal settings. This area covered methodological advances that improve the ability to track stem cells after transplantation, measure their fate and function over time, assess safety issues (including abnormal growth, ectopic tissue formation, or tumorigenicity), and evaluate immune interactions and host responses. In practice, this could include new imaging and labeling approaches, improved assays for stem cell potency and in vivo function, better transplantation delivery methods, and tools that support rigorous, reproducible evaluation of stem cell behavior within living organisms.
A third focal area was improving existing animal models and developing new models of human disease that are better suited for testing stem cell-based therapeutic applications. This reflects a recognition that many traditional animal models do not adequately capture the complexity of human disease progression, tissue microenvironments, comorbidities, or clinically relevant endpoints. The FOA aimed to stimulate work that produces disease models more appropriate for regenerative medicine studies, such as models with injury mechanisms and timelines closer to human pathology, models that allow meaningful functional outcome measurements, and models that support testing of clinically realistic delivery routes, dosing strategies, and follow-up periods.
Administratively, this was a discretionary grant opportunity using the NIH R01 mechanism. It had no cost-sharing or matching requirement. The opportunity was posted on February 11, 2013, created on February 14, 2013, and had an original and final closing date of May 7, 2016, with an archive date of June 7, 2016. It was associated with multiple CFDA program areas spanning oral health, research infrastructure, cardiovascular disease, musculoskeletal and skin diseases, diabetes and digestive and kidney diseases, and broader biomedical research and training, reflecting how stem cell-based regenerative approaches cut across many organ systems and NIH institute missions.
Eligibility was broad and included many types of U.S. and non-U.S. organizations. Eligible applicants included public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status), for-profit organizations (including small businesses), state and local government entities, independent school districts, public housing authorities, and tribal governments and tribal organizations. The FOA also explicitly listed additional eligible groups such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, Asian American and Native American Pacific Islander-serving institutions (AANAPISIs), tribally controlled colleges and universities (TCCUs), faith-based and community-based organizations, regional organizations, and U.S. territories or possessions. Foreign organizations and foreign institutions were eligible to apply, and non-U.S. components of U.S. organizations were also eligible; foreign components as defined by NIH policy were allowed, reinforcing NIH interest in leveraging global expertise in animal modeling and stem cell science.
The sponsoring agency was the National Institutes of Health. The full announcement was available through the NIH Grants Guide (linked in the source as http://grants.nih.gov/grants/guide/pa-files/PAR-13-114.html). For technical issues accessing or linking to the announcement, the listed contact point was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-13-114.
Which grant mechanism does this opportunity use?
This opportunity supported applications under the NIH Research Project Grant (R01) mechanism.
What is the main purpose of this FOA?
The main purpose was to make animal studies more useful and reliable for translating stem cell discoveries into real regenerative medicine therapies, by improving the scientific bridge between preclinical animal research and human clinical applications.
What kinds of research were encouraged under this FOA?
The FOA emphasized three broad areas: (1) comparative studies of animal versus human stem cells, (2) technologies to improve stem cell characterization and transplantation studies in animals, and (3) improved or new animal disease models better suited for testing stem cell-based therapeutic applications.
Did this FOA emphasize comparing animal and human stem cells?
Yes. A major emphasis was comparative work that directly examines similarities and differences between animal and human stem cells, to help identify model systems that are most predictive for translation to humans.
What stem cell characteristics were highlighted for comparative characterization?
The FOA described characterizing stem cell properties such as differentiation potential, self-renewal, lineage stability, functional integration, and responses to injury or disease environments.
Why did NIH prioritize comparative animal-human stem cell studies?
The practical goal was to map where animal stem cell behavior matches human biology (and where it does not), so researchers can choose the most predictive species, tissue types, and experimental systems for particular diseases or therapeutic strategies.
What types of technology development were encouraged?
The FOA encouraged creation and refinement of technologies that enable better stem cell characterization and transplantation in animal settings, including methods to track transplanted cells, measure fate and function over time, assess safety, and evaluate immune interactions and host responses.
Did the FOA include work on tracking stem cells after transplantation?
Yes. It specifically referenced improving the ability to track stem cells after transplantation and to measure their fate and function over time in vivo.
Were safety assessments part of the scope?
Yes. The FOA explicitly referenced assessing safety issues, including abnormal growth, ectopic tissue formation, and tumorigenicity.
Did NIH mention immune interactions and host responses?
Yes. The FOA included evaluating immune interactions and host responses as part of improving stem cell evaluation in animal studies.
What are examples of methodological advances mentioned in the FOA?
Examples described included new imaging and labeling approaches, improved assays for stem cell potency and in vivo function, better transplantation delivery methods, and tools that support rigorous, reproducible evaluation of stem cell behavior in living organisms.
Did this FOA support improving existing animal models of human disease?
Yes. A focal area was improving existing animal models and developing new models of human disease that are better suited for testing stem cell-based therapeutic applications.
Why improve or develop new disease models for regenerative medicine studies?
The FOA noted that many traditional animal models do not adequately capture the complexity of human disease progression, tissue microenvironments, comorbidities, or clinically relevant endpoints, which can limit translational relevance for stem cell-based interventions.
What qualities did NIH want in improved animal disease models?
The FOA described models with injury mechanisms and timelines closer to human pathology, models that allow meaningful functional outcome measurements, and models that support testing of clinically realistic delivery routes, dosing strategies, and follow-up periods.
Was cost sharing or matching required?
No. The FOA stated there was no cost-sharing or matching requirement.
Is this a discretionary grant opportunity?
Yes. Administratively, it was described as a discretionary grant opportunity using the NIH R01 mechanism.
When was this funding opportunity posted?
It was posted on February 11, 2013.
When was the opportunity created?
It was created on February 14, 2013.
What were the original and final closing dates?
The FOA had an original and final closing date of May 7, 2016.
When was the opportunity archived?
The archive date was June 7, 2016.
Which agency sponsored this opportunity?
The sponsoring agency was the National Institutes of Health (NIH).
What program areas (CFDA-related areas) were associated with this FOA?
The opportunity was associated with multiple CFDA program areas spanning oral health, research infrastructure, cardiovascular disease, musculoskeletal and skin diseases, diabetes and digestive and kidney diseases, and broader biomedical research and training.
Why did the FOA span multiple CFDA program areas?
The FOA reflected that stem cell-based regenerative approaches cut across many organ systems and NIH institute missions, so it aligned with several program areas rather than a single disease category.
Who was eligible to apply?
Eligibility was broad and included many types of U.S. and non-U.S. organizations, including public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (including small businesses), and various government entities.
Are state and local governments eligible?
Yes. The FOA listed state and local government entities as eligible applicants.
Are tribal governments and tribal organizations eligible?
Yes. The FOA listed tribal governments and tribal organizations as eligible applicants.
Are independent school districts eligible?
Yes. Independent school districts were explicitly listed as eligible applicants.
Are public housing authorities eligible?
Yes. Public housing authorities were explicitly listed as eligible applicants.
Are Historically Black Colleges and Universities (HBCUs) eligible?
Yes. HBCUs were explicitly listed among eligible applicant types.
Are Hispanic-serving institutions eligible?
Yes. Hispanic-serving institutions were explicitly listed among eligible applicant types.
Are Alaska Native and Native Hawaiian-serving institutions eligible?
Yes. Alaska Native and Native Hawaiian-serving institutions were explicitly listed among eligible applicant types.
Are AANAPISIs (Asian American and Native American Pacific Islander-serving institutions) eligible?
Yes. AANAPISIs were explicitly listed among eligible applicant types.
Are tribally controlled colleges and universities (TCCUs) eligible?
Yes. TCCUs were explicitly listed among eligible applicant types.
Are faith-based and community-based organizations eligible?
Yes. The FOA explicitly listed faith-based and community-based organizations as eligible.
Are regional organizations eligible?
Yes. Regional organizations were explicitly listed as eligible.
Are U.S. territories or possessions eligible?
Yes. U.S. territories or possessions were explicitly listed as eligible.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The FOA stated that foreign organizations and foreign institutions were eligible to apply.
Are non-U.S. components of U.S. organizations allowed?
Yes. The FOA stated that non-U.S. components of U.S. organizations were eligible, and that foreign components (as defined by NIH policy) were allowed.
Where can applicants find the full announcement?
The full announcement was available through the NIH Grants Guide at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-114.html
Who should be contacted for technical issues accessing or linking to the announcement?
For technical issues accessing or linking to the announcement, the listed contact was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.
Browse more opportunities from the same category: Food and Nutrition Health
Next opportunity: Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R21)
Previous opportunity: Improvement of Animal Models for Stem Cell Based Regenerative Medicine (R24)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 114
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 114) also looked into and applied for these:
| Funding Opportunity |
|---|
| Undergraduate Summer Institutes in Kidney, Urologic and Hematologic Diseases (R25) Apply for RFA DK 13 005 Funding Number: RFA DK 13 005 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Acute Kidney Injury in Older Adults (R01) Apply for PA 13 141 Funding Number: PA 13 141 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Addressing Health Disparities in NIDDK Diseases (R01) Apply for PA 13 183 Funding Number: PA 13 183 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Planning Grants for Translating CKD Research into Improved Clinical Outcomes (R34) Apply for RFA DK 13 002 Funding Number: RFA DK 13 002 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $225,000 |
| Biomarkers for Diabetes, Digestive, Kidney and Urologic Diseases Using Biosamples from the NIDDK Repository (R01) Apply for PAR 13 228 Funding Number: PAR 13 228 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $250,000 |
| United States Renal Data System (USRDS) Special Study Centers (U01) Apply for RFA DK 13 008 Funding Number: RFA DK 13 008 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Network Hub (U01) Apply for RFA DK 13 009 Funding Number: RFA DK 13 009 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $2,000,000 |
| Type 1 Diabetes TrialNet Clinical Centers (U01) Apply for RFA DK 13 010 Funding Number: RFA DK 13 010 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $200,000 |
| NIDDK Program Projects (P01) Apply for PAR 13 266 Funding Number: PAR 13 266 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| NIDDK Multi Center Clinical Study Implementation Planning Cooperative Agreements (U34) Apply for PAR 13 268 Funding Number: PAR 13 268 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $225,000 |
| Limited Competition for the Continuation of a National Endoscopic Database (U01) Apply for RFA DK 13 504 Funding Number: RFA DK 13 504 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Diabetes Research Centers (P30) Apply for RFA DK 13 004 Funding Number: RFA DK 13 004 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Continuation of ChiLDReN, the Childhood Liver Disease Research Network (U01) Apply for RFA DK 13 011 Funding Number: RFA DK 13 011 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Continuation of the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)(U01) Apply for RFA DK 13 503 Funding Number: RFA DK 13 503 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Gut Microbiota Derived Factors in the Integrated Physiology and Pathophysiology of Diseases within NIDDKs Mission (R01) Apply for PAR 13 293 Funding Number: PAR 13 293 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Limited Competition Chronic Kidney Disease (CKD) Biomarkers Consortium Data Coordinating Center (U01) Apply for RFA DK 13 506 Funding Number: RFA DK 13 506 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24) Apply for PAR 13 305 Funding Number: PAR 13 305 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
| Improving Diabetes Management in Young Children with Type 1 Diabetes (DP3) Apply for RFA DK 13 022 Funding Number: RFA DK 13 022 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $1,400,000 |
| Understanding Barriers and Facilitators to Type 1 Diabetes Management in Adults (DP3) Apply for RFA DK 13 023 Funding Number: RFA DK 13 023 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: $5,000,000 |
| Limited Competition of the MAPP Research Network(U01) Apply for RFA DK 13 507 Funding Number: RFA DK 13 507 Agency: National Institutes of Health Category: Food and Nutrition Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 114", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.